Restricted accessResearch articleFirst published online 2021-03
Cell Surface Glycoprotein CD24 Marks Bone Marrow-Derived Human Mesenchymal Stem/Stromal Cells with Reduced Proliferative and Differentiation Capacity In Vitro
Bone marrow-derived mesenchymal stem/stromal cells (BMSCs) are fundamental to bone regenerative therapies, tissue engineering, and postmenopausal osteoporosis. Donor variation among patients, cell heterogeneity, and unpredictable capacity for differentiation reduce effectiveness of BMSCs for regenerative cell therapies. The cell surface glycoprotein CD24 exhibits the most prominent differential expression during osteogenic versus adipogenic differentiation of human BMSCs. Therefore, CD24 may represent a selective biomarker for subpopulations of BMSCs with increased osteoblastic potential. In undifferentiated human BMSCs, CD24 cell surface expression is variable among donors (range: 2%–10%) and increased by two to fourfold upon osteogenic differentiation. Strikingly, FACS sorted CD24pos cells exhibit delayed mineralization and reduced capacity for adipocyte differentiation. RNAseq analysis of CD24pos and CD24neg BMSCs identified a limited number of genes with increased expression in CD24pos cells that are associated with cell adhesion, motility, and extracellular matrix. Downregulated genes are associated with cell cycle regulation, and biological assays revealed that CD24pos cells have reduced proliferation. Hence, expression of the cell surface glycoprotein CD24 identifies a subpopulation of human BMSCs with reduced capacity for proliferation and extracellular matrix mineralization. Functional specialization among BMSCs populations may support their regenerative potential and therapeutic success by accommodating cell activities that promote skeletal tissue formation, homeostasis, and repair.
Get full access to this article
View all access options for this article.
References
1.
SteinertAF, RackwitzL, GilbertF, NöthU and TuanRS. (2012). Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. Stem Cells Transl Med, 1:237–247.
2.
Fernández ValloneVB, RomaniukMA, ChoiH, LabovskyV, OtaeguiJ and ChasseingNA. (2013). Mesenchymal stem cells and their use in therapy: what has been achieved?. Differentiation, 85:1–10.
3.
MurphyMB, MoncivaisK and CaplanAI. (2013). Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med, 45:e54.
4.
SamsonrajRM, RaghunathM, NurcombeV, HuiJH, van WijnenAJ and CoolSM. (2017). Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med, 6:2173–2185.
5.
PittengerMF, MackayAM, BeckSC, JaiswalRK, DouglasR, MoscaJD, MoormanMA, SimonettiDW, CraigS and MarshakDR. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284:143–147.
6.
StriogaM, ViswanathanS, DarinskasA, SlabyO and MichalekJ. (2012). Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev, 21:2724–2752.
7.
BillingAM, Ben HamidaneH, DibSS, CottonRJ, BhagwatAM, KumarP, HayatS, YousriNA, GoswamiN, et al. (2016). Comprehensive transcriptomic and proteomic characterization of human mesenchymal stem cells reveals source specific cellular markers. Sci Rep, 6:21507.
8.
SivasubramaniyanK, LehnenD, GhazanfariR, SobiesiakM, HarichandanA, MorthaE, PetkovaN, GrimmS, CerabonaF, et al. (2012). Phenotypic and functional heterogeneity of human bone marrow- and amnion-derived MSC subsets. Ann N Y Acad Sci, 1266:94–106.
9.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniFC, KrauseDS, DeansRJ, KeatingA, ProckopDJ and HorwitzEM. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
10.
MushaharyD, SpittlerA, KasperC, WeberV and CharwatV. (2018). Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A, 93:19–31.
11.
RojewskiMT, WeberBM and SchrezenmeierH. (2008). Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemother, 35:168–184.
12.
CamilleriET, GustafsonMP, DudakovicA, RiesterSM, GarcesCG, ParadiseCR, TakaiH, KarperienM, CoolS, et al. (2016). Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res Ther, 7:107.
13.
SamsonrajRM, ParadiseCR, DudakovicA, SenB, NairAA, DietzAB, DeyleDR, CoolSM, RubinJ and van WijnenAJ. (2018). Validation of osteogenic properties of cytochalasin D by high-resolution RNA-sequencing in mesenchymal stem cells derived from bone marrow and adipose tissues. Stem Cells Dev, 27:1136–1145.
14.
DudakovicA, CamilleriE, RiesterSM, LewallenEA, KvashaS, ChenX, RadelDJ, AndersonJM, NairAA, et al. (2014). High-resolution molecular validation of self-renewal and spontaneous differentiation in clinical-grade adipose-tissue derived human mesenchymal stem cells. J Cell Biochem, 115:1816–1828.
15.
BusserH, NajarM, RaicevicG, PietersK, Velez PomboR, PhilippartP, MeulemanN, BronD and LagneauxL. (2015). Isolation and characterization of human mesenchymal stromal cell subpopulations: comparison of bone marrow and adipose tissue. Stem Cells Dev, 24:2142–2157.
16.
BakshD, YaoR and TuanRS. (2007). Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells, 25:1384–1392.
17.
NingH, LinG, LueTF and LinC-S. (2011). Mesenchymal stem cell marker Stro-1 is a 75kd endothelial antigen. Biochem Biophys Res Commun, 413:353–357.
18.
KuciS, KuciZ, KreyenbergH, DeakE, PutschK, HueneckeS, AmaraC, KollerS, RettingerE, et al. (2010). CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica, 95:651–659.
19.
GangEJ, BosnakovskiD, FigueiredoCA, VisserJW and PerlingeiroRCR. (2007). SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood, 109:1743–1751.
20.
LvF-J, TuanRS, CheungKMC and LeungVYL. (2014). Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells, 32:1408–1419.
21.
van de PeppelJ, StriniT, TilburgJ, WesterhoffH, van WijnenAJ and van LeeuwenJP. (2017). Identification of three early phases of cell-fate determination during osteogenic and adipogenic differentiation by transcription factor dynamics. Stem Cell Reports, 8:947–960.
22.
AignerS, SthoegerZM, FogelM, WeberE, ZarnJ, RuppertM, ZellerY, VestweberD, StahelR, SammarM and AltevogtP. (1997). CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood, 89:3385–3395.
23.
BruedigamC, van DrielM, KoedamM, van de PeppelJ, van der EerdenBCJ, Eijken and JM, van LeeuwenPTM. (2011). Basic techniques in human mesenchymal stem cell cultures: differentiation into osteogenic and adipogenic lineages, genetic perturbations, and phenotypic analyses. Curr Protoc Stem Cell Biol Chapter, 1:Unit1H.3.
24.
LoveMI, HuberW and AndersS. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15:550.
25.
RitchieME, PhipsonB, WuD, HuY, LawCW, ShiW and SmythGK. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 43:e47.
26.
DuperrayC, BoironJM, BoucheixC, CantaloubeJF, Lavabre-BertrandT, AttalM, BrochierJ, MaraninchiD, BatailleR and KleinB. (1990). The CD24 antigen discriminates between pre-B and B cells in human bone marrow. J Immunol, 145:3678–3683.
27.
LiuF, MalavalL, GuptaAK and AubinJE. (1994). Simultaneous detection of multiple bone-related mRNAs and protein expression during osteoblast differentiation: polymerase chain reaction and immunocytochemical studies at the single cell level. Dev Biol, 166:220–234.
28.
LiuF, MalavalL and AubinJE. (1997). The mature osteoblast phenotype is characterized by extensive plasticity. Exp Cell Res, 232:97–105.
29.
CoteAJ, McLeodCM, FarrellMJ., McClanahanPD, DunaginMC, RajA and MauckRL. (2016). Single-cell differences in matrix gene expression do not predict matrix deposition. Nat Commun, 7:10865.
30.
SchäckLM, BuettnerM, WirthA, NeunaberC, KrettekC, HoffmannA and NoackS. (2016). Expression of CD24 in human bone marrow-derived mesenchymal stromal cells is regulated by TGFβ3 and induces a myofibroblast-like genotype. Stem Cells Int, 2016:1319578.
31.
KayR, RostenPM and HumphriesRK. (1991). CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol, 147:1412–1416.
32.
GilliamDT, MenonV, BretzNP and PruszakJ. (2017). The CD24 surface antigen in neural development and disease. Neurobiol Dis, 99:133–144.
33.
BerryR and RodehefferMS. (2013). Characterization of the adipocyte cellular lineage in vivo. Nat Cell Biol, 15:302–308.
34.
WetzigA, AlaiyaA, Al-AlwanM, PradezCB, PulicatMS, Al-MazrouA, ShinwariZ, SleimanGM, GhebehH, et al. (2013). Differential marker expression by cultures rich in mesenchymal stem cells. BMC Cell Biol, 14:54.
35.
SubramanianA, FongC-Y, BiswasA and BongsoA. (2015). Comparative characterization of cells from the various compartments of the human umbilical cord shows that the Wharton's Jelly compartment provides the best source of clinically utilizable mesenchymal stem cells. PLoS One, 10:e0127992.
36.
MestasJ and HughesCCW. (2004). Of mice and not men: differences between mouse and human immunology. J Immunol, 172:2731.
37.
GinisI, LuoY, MiuraT, ThiesS, BrandenbergerR, Gerecht-NirS, AmitM, HokeA, CarpenterMK, Itskovitz-EldorJ and RaoMS. (2004). Differences between human and mouse embryonic stem cells. Dev Biol, 269:360–380.
38.
OhlC, AlbachC, AltevogtP and SchmitzB. (2003). N-glycosylation patterns of HSA/CD24 from different cell lines and brain homogenates: a comparison. Biochimie, 85:565–573.
39.
BarkeerS, ChughS, BatraSK and PonnusamyMP. (2018). Glycosylation of cancer stem cells: function in stemness, tumorigenesis, and metastasis. Neoplasia, 20:813–825.
40.
SchellenbergA, StiehlT, HornP, JoussenS, PalluaN, HoAD and WagnerW. (2012). Population dynamics of mesenchymal stromal cells during culture expansion. Cytotherapy, 14:401–411.
41.
DuscherD, RennertRC, JanuszykM, AnghelE, MaanZN, WhittamAJ, PerezMG, KosarajuR, HuMS, et al. (2014). Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells. Sci Rep, 4:7144.
42.
SatoT, van EsJH, SnippertHJ, StangeDE, VriesRG, van den BornM, BarkerN, ShroyerNF, van de Wetering M and CleversH. (2011). Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature, 469:415–418.
43.
Al-HajjM, WichaMS, Benito-HernandezA, MorrisonSJ and ClarkeMF. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A, 100:3983–3988.
44.
ZhouZ, LiY, KuangM, WangX, JiaQ, CaoJ, HuJ, WuS, WangZ and XiaoJ. (2020). The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma. EBioMedicine, 51:102598.
45.
OkabeH, AokiK, YogosawaS, SaitoM, MarumoK and YoshidaK. (2018). Downregulation of CD24 suppresses bone metastasis of lung cancer. Cancer Sci, 109:112–120.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
